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Abstract
Background: Reports from urban medical centers suggest that methicillin-resistant Staphylococcus aureus (MRSA)
has become the most common cause of skin and soft-tissue infections (SSTIs). Risk factors for MRSA have been
identified but have not been clinically useful.
Findings: From May 2006-April 2007, we performed an observational study of 529 SSTIs among ambulatory
patients in the urgent care departments of a large suburban primary-care practice. SSTIs were included if they
produced pus or fluid. The proportion of MRSA was determined overall (defined as prevalence) and by SSTI
diagnosis. Potential risk factors for MRSA were examined with multivariate analysis, and descriptive statistics were
generated for follow-up and abscess management. The prevalence of MRSA was 22% and did not rise during the
study. MRSA was isolated from 36% of abscesses, 15% of cellulitis, and 14% of other SSTIs. Independent risk factors
for MRSA included a prior history of MRSA (adjusted odds ratio [aOR], 41.05; 95% confidence interval [CI], 11.4-
147.3), a close contact with prior MRSA (aOR, 12.83; 95% CI, 4.2-39.2), erythema ≥10 cm (aOR, 2.59; 95% CI, 1.5-4.4),
and abscess diagnosis (aOR, 3.19; 95% CI, 2.1-5.0). Prior MRSA had a positive predictive value of 88% for current
MRSA. When both abscess diagnosis and erythema ≥10 cm were present, the proportion of MRSA was 59%. The
vast majority of SSTIs (96 percent) resolved or improved within one week. Most abscesses, even small ones, were
treated with antibiotics. Resource utilization was highest in those abscesses with erythema ≥10 cm.
Conclusions: The prevalence of MRSA is relatively low among SSTIs in suburban primary care. However, MRSA is
common in the subgroup of abscesses with large erythema. While the effectiveness of adjunctive antibiotic
therapy for large abscesses is unknown, drugs chosen for these infections should be active against MRSA. Most
non-abscess SSTIs do not require treatment with a MRSA-active drug, and antibiotics are probably overused for
small abscesses. A history of prior MRSA should be recorded in a patient’s health record.
Background
The prevalence of methicillin-resistant Staphylococcus
aureus (MRSA) in skin and soft-tissue infections (SSTIs)
has reached epidemic proportions in the United States
(US) according to studies published since 2004 [1-7].
The emergence of MRSA has been particularly rapid in
some areas [3,4,7]. MRSA is resistant to beta-lactam
antibiotics such as cephalexin and dicloxacillin which
are traditionally used to treat SSTIs [8]. With the rising
prevalence of MRSA, many SSTIs may be inadequately
treated if clinicians continue to rely on beta-lactam
agents. Conversely, SSTIs not caused by MRSA may be
treated unnecessarily with MRSA-active drugs.
Most MRSA isolates from SSTIs in the United States
are descended from a clone of MRSA known as USA-
300 [5,6]. These isolates contain the SCCmec IV gene
complex which conveys methicillin resistance [2,9], and
are termed community-associated MRSA (CA-MRSA)
for lack of traditional risk factors linked to healthcare-
associated infection [8,9]. While CA-MRSA isolates are
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usually susceptible to tetracycline and trimethoprim-sul-
famethoxazole (TMP/SMX), and have been universally
susceptible to vancomycin, substantial resistance to both
clindamycin and fluoroquinolones has been reported
[2,4,6,7]. Multiple risk factors for CA-MRSA have been
identified in both outbreak [10-12] and endemic
[2,5,6,13-16] settings, but they appear to have limited
clinical usefulness [6,14]. Follow-up data suggest timely
resolution in most SSTIs caused by MRSA [6,17-20].
However, there have been reports of delayed treatment
response [21-24], high hospitalization rates [4,25], and
severe infections [26,27].
Early studies of endemic CA-MRSA were performed
primarily in outpatient clinics, emergency departments,
and hospitals associated with urban medical centers that
serve indigent populations [1-7]. In addition, the types
and sizes of SSTIs examined in some of these studies
were not clearly defined [1,3-5,7]. To address these lim-
itations, we investigated the epidemiology of MRSA in
SSTIs among ambulatory patients from suburban areas
in the San Francisco Bay Area (Bay Area). We classified
SSTIs by diagnosis group and maximum erythema size,
and also described initial treatment decisions and
resource utilization in the management of abscesses.
Methods
This was an observational study of purulent or fluid-pro-
ducing SSTIs that were sampled for bacterial culture
among ambulatory patients from May 1, 2006 through
April 30, 2007. Incision and drainage (I&D) of abscesses
and culturing of pus and fluid from SSTIs were usual care
prior to the study. Clinical decisions regarding procedures,
cultures, antibiotics, and charting in the electronic health
record (EHR) remained at the discretion of providers.
The study took place in the adult and pediatric urgent
care departments (urgent care) of the Palo Alto Medical
Foundation, Palo Alto Division (PAMF-PA), which have
over 50,000 patient visits annually. PAMF-PA provides
primary and specialty care to an ambulatory patient
population of approximately 300,000 persons in the Bay
Area, The primary care providers (PCPs) in the family
medicine, internal medicine, and pediatrics departments
at PAMF-PA frequently refer patients to urgent care for
I&D of abscesses and for intravenous infusions of anti-
biotics. The study was funded by PAMF-PA.
Patients of any age were considered for inclusion in
the study if a new SSTI was diagnosed by an urgent
care provider and a bacterial culture was obtained from
the infection site. An SSTI was considered new if there
was no previous history of SSTI, or if greater than one
month had elapsed since resolution of erythema and
pus or fluid in a previous SSTI. Patients were excluded
if they had a nonbacterial skin disorder (e.g. herpes sim-
plex infection or trauma without infection) or a
noncutaneous bacterial infection (e.g. vaginitis or peri-
rectal abscess). Patients were not excluded if they had a
history of risk factors for healthcare-associated MRSA.
The proportions of MRSA, methicillin-sensitive Sta-
phylococcus aureus (MSSA), and Streptococcal species
were determined overall and by three diagnosis groups:
abscesses (discrete collections of pus including furuncles
and carbuncles), cellulitis (spreading erythema with bul-
lous or open purulent, moist, or fluid-producing areas),
and other SSTIs (felon, folliculitis, impetigo, paronychia,
septic bursitis, inflamed sebaceous cyst, and miscella-
neous). The overall proportion of a bacterial isolate was
termed its prevalence. Demographics and potential risk
factors for MRSA versus non-MRSA culture results
were examined. Erythema, an easily ascertained measure
of infection size, was defined as the maximum dimen-
sion of erythema in any direction measured in cm. If
erythema was not recorded in the EHR, an estimate was
imputed using standard anthropometric tables [28]
where possible. Erythema ≥10 cm was considered
“large” erythema. Injection drug use was not examined
because a previous case series of MRSA SSTIs at our
institution revealed no patient with this history (unpub-
lished data). Follow-up status was assessed as better or
resolved, worse or no change, or lost to follow-up at last
patient contact within seven days of the initial visit.
Initial treatment selections for abscesses included anti-
biotic therapy (started or continued at the initial visit),
I&D, both antibiotic and I&D, or neither antibiotic nor
I&D. An antibiotic selection was considered “active” if
the isolate was confirmed susceptible to the drug by
laboratory testing. Repeat I&D and ≥3 follow-up visits
were considered variables potentially affected by initial
antibiotic selections. Resources utilized for abscess man-
agement (in addition to an oral antibiotic and/or initial
I&D) were outpatient intravenous therapy (IV), hospita-
lization, repeat I&D, and ≥3 follow-up visits. Resource
utilization was described by erythema size.
Reports listing all wound and body fluid culture
results were reviewed thrice weekly to identify possible
SSTIs for the study. Inclusion of SSTIs and assignment
of diagnosis group was based on initial provider assess-
ment and consensus between two authors (CW and
PK). The visit during which the initial bacterial culture
was performed was the initial visit. Specimens for aero-
bic culture were obtained with a Culturette EZ II™
transport swab (Becton Dickinson, Franklin Lakes, New
Jersey) and were processed and cultured at the Mills-
Peninsula Hospital Laboratory (San Mateo, CA) utilizing
standard techniques [29]. The Dade Behring Microscan
system was used to determine antibiotic susceptibilities.
The D-zone test was done on isolates that were erythro-
mycin-resistant and clindamycin-susceptible to confirm
clindamycin susceptibility.
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A standardized SSTI template was available for provi-
der use in the EHR. Data were extracted from the SSTI
template or other EHR notes. As a proxy for individual
income and education data, the socioeconomic status
(SES) of the zip codes in which patients resided was
examined using the US Postal Service [30] and US Cen-
sus 2000 [31]. Follow-up status was determined by EHR
review and telephone calls made on days 3 and 7 after
the initial visit. Up to two calls per patient were made
on both days. Initial treatment selections and resource
utilization for abscesses were recorded. The total num-
ber of I&D procedures performed in urgent care during
the study period was provided by the information tech-
nology department at PAMF-PA.
All SSTIs, including those with no growth, were
included in the analysis. Descriptive statistics were gen-
erated after data entry in Epi Info software, version
3.3.2, February 9, 2005 (CDC, Atlanta, Georgia). Analy-
sis of potential risk factors for MRSA was performed for
MRSA versus non-MRSA and for MRSA versus MSSA.
Continuous variables were analyzed with the t-test and
dichotomous variables with the chi-square test. Multi-
variate analysis was performed using logistic regression
with variables either considered clinically important or
with a significant association to specific outcome vari-
ables at the 0.05 significance level, using SAS, version
8.2 (Cary, North Carolina). Odds ratios (OR) and 95
percent confidence intervals (CI) were calculated. Sepa-
rate models were created for demographical/historical
variables and clinical variables.
The Institutional Review Board of the PAMF-PA
approved the study. Verbal consent was obtained for fol-
low-up telephone calls.
Results
There were 513 patients (Table 1) with 529 confirmed
SSTIs (Figure 1) during the 12 months of the study. Zip
codes were available for 502 patients, 468 (93 per cent)
of whom resided in the Bay Area. Of the Bay Area
patients, 428 (91 percent) had addresses outside the
major cities of San Francisco, San Jose, and Oakland.
The vast majority of Bay Area patients lived in zip codes
with incomes and educational levels above the national
median. Nearly 60 percent of patients had a designated
PCP at PAMF-PA. SSTIs were divided almost equally
among abscesses, cellulitis, and other SSTIs (Figure 1).
During the study, 362 I&D procedures were performed
for SSTIs in urgent care. Of these, 264 (73 percent) had
a bacterial culture, and 245 (68 percent) were included
in the study.
Ninety percent of cultures were positive for at least
one bacterial isolate. The prevalence of MRSA was 22
percent, lower than that of MSSA but higher than
Streptococcal species (Table 2). MRSA accounted for
only 42 percent of S. aureus isolates. No culture was
positive for both MRSA and MSSA, while one culture
grew MRSA and a Streptococcal species. Other organ-
isms in the non-MRSA group that were isolated more
than once included coagulase-negative Staphylococci
(100), E. coli (13), diphtheroids (8), Pseudomonas spp.
(8), Enterobacter spp. (5), Peptostreptococcus spp. (5), S.
lugdunensis (4), H. influenzae (3), Proteus mirabilis (3),
Serratia spp. (3), Bacteroides spp. (2), Pasturella multo-
cida (2), and Propionibacterium spp. (2).
The proportion of MRSA was highest in abscesses and
lower in cellulitis and other SSTIs. If cases of folliculitis
(10 of 20 [50 percent] positive for MRSA) were excluded
from the other SSTIs group, the proportion of MRSA
was only 8 percent. The monthly prevalence of MRSA
and the monthly frequency of all SSTIs showed no over-
all increase during the study period.
Cumulative susceptibilities for MRSA isolates were
100 percent to TMP/SMX and vancomycin, 94 percent
to tetracycline, 88 percent to clindamycin, and 45 per-
cent to levofloxacin. Among the 14 MRSA isolates resis-
tant to clindamycin, five were identified as having
inducible resistance by the D-zone test.
Independent demographical and historical risk factors
for MRSA versus non-MRSA were age <65 years, a
reported insect bite, a prior history of MRSA, a close
contact with a history of MRSA, and a current antibiotic
(in all cases a drug started previously for the SSTI)
(Table 3). Prior MRSA had a positive predictive value
for current MRSA of 88 percent. Admission to a hospi-
tal, nursing home, or dialysis unit within the last 12
months was rare regardless of culture result. Indepen-
dent clinical risk factors for MRSA were erythema ≥10
cm (80 of 500 [16 percent] erythema measurements
were imputed) and abscess diagnosis (Table 4). The








Male sex 287 (56)
Primary care at PAMF-PA 298 (58)
High income zip codes*(1) 463 (99)
High education zip codes*(2) 459 (98)
Abbreviation: PAMF-PA, Palo Alto Medical Foundation, Palo Alto division.
*Based on 468 Bay Area residents, proportion in zip code of (1) households
with median household income > national median.
household income; (2) residents aged ≥25 yrs with a bachelor’s degree or
higher greater than the proportion nationwide.
(Definitions from the U.S.Census.).
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proportion of MRSA varied by erythema size in
abscesses and was highest (59 percent) in those with
≥10 cm erythema (Table 5). The same risk factors for
MRSA were identified in an analysis of MRSA versus
MSSA (results not shown) aside from age <65. Providers
used the EHR SSTI template to record historical and
clinical findings in 280 of 529 SSTI (53 percent). Tem-
plate use was not associated with MRSA (p = 0.10).
Follow-up was available for 399 (75 percent) of 529
SSTIs, 383 (96 percent) of which improved or resolved
within seven days of initial visit, with no difference
between MRSA and non-MRSA SSTIs (p = 0.60).
Patients lost to follow-up were less likely to have
erythema ≥10 cm (p = 0.004).
Initial treatment of the 185 abscesses consisted of
antibiotic therapy in 172 (93 percent), I&D in 154 (83
percent), both antibiotic therapy and I&D in 142 (77
percent), and neither in one (1 percent). Empirical anti-
biotic coverage was common for abscesses at all levels
of erythema size: 79 of 91 (87 percent) with 0-4 cm
erythema, 42 of 43 (98 percent) with 5-9 cm erythema,
and 44 of 44 (100 percent) with ≥10 cm erythema. Beta-
lactam antibiotics, TMP/SMX, and combinations of
beta-lactam antibiotics with drugs typically active against


















Figure 1 Distribution of skin and soft-tissue infections within the study. Abbreviations: SSTI, skin and soft-tissue infection. *Felon (5),
folliculitis (20), impetigo (25), finger paronychia (45), toe paronychia (14), olecranon bursitis (14), prepatellar bursitis (3), sebaceous cyst (32),
miscellaneous (3).
Table 2 Proportion of bacterial isolates in skin and soft-
tissue infections overall and by diagnosis group






All SSTI (N = 529) 115 (22) 161(30) 69 (13)
Abscess (N = 185) 66 (36) 49 (26) 19 (10)
Cellulitis (N = 183) 27 (15) 58 (32) 25 (14)
Other SSTIs
(N = 161)
22 (14) 54 (34) 25 (16)
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; MSSA,
methicillin-sensitive Staphylococcus aureus; Strep, Streptococcal species; SSTIs,
skin and soft-tissue infections.
Weiss et al. BMC Research Notes 2011, 4:33
http://www.biomedcentral.com/1756-0500/4/33
Page 4 of 9
minority of abscesses (26 [14 percent]) were treated with
outpatient intravenous antibiotic infusion, most often
(24 of 26) at the initial visit. Only two patients were
hospitalized, one at the initial visit, and one a week after
the initial visit, the latter for a drug reaction.
Of 152 abscesses with follow-up information, 149 (98
percent) improved or resolved within seven days, 19 (13
percent) required repeat I&D, and 57 (38 percent) had
≥3 follow-up visits. The initial antibiotic selection was
active against the isolate in 110 of 125 (88 percent)
abscesses with susceptibility results. However, an active
drug regimen did not lower the risk for repeat I&D or
for ≥3 follow-up visits (p = 0.09 and p = 0.27 respec-
tively). Resource utilization varied by erythema size and
was highest in abscesses with erythema ≥10 cm (Table
7). Abscesses caused by MRSA were more likely to
require utilization of any resource (31 of 60 [52 per-
cent]) than non-MRSA abscesses (30 of 92 [33 percent])
(p = 0.02).
Discussion
In this study of purulent or fluid-producing SSTIs, the
prevalence of MRSA was 22 percent. This is substan-
tially below the 42 to 64 percent range previously
Table 3 Demographical and historical variables: overall, and MRSA vs. non-MRSA
All isolates, No. (%) MRSA, No. (%) Non-MRSA, No. (%) Unadjusted OR (95% CI) Adjusted OR (95% CI)*
(N = 529) (N = 115) (N = 414)
Age < 65 years 432 (82) 104 (90) 328 (79) 2.47 (1.3-4.8) 2.25 (1.0-4.9), P = 0.002
Male sex 296 (56) 67 (58) 229 (55) 1.12 (0.7-1.7) -
Itching† 92 (17) 29 (25) 63 (15) 1.88 (1.1-3.1) -
Trauma† 167 (32) 24 (21) 143 (35) 0.50 (0.3-0.8) -
Surgery† 37 (7) 5 (4) 32 (8) 0.54 (0.2-1.4) -
Insect bite 75 (14) 33 (29) 42 (10) 3.56 (2.1-6.0) 4.18 (2.4-7.4), P < 0.001
Prior MRSA 26 (5) 23 (20) 3 (1) 34.3 (10.1-116.5) 41.05 (11.4-147.3), P < 0.001
Contact MRSA‡ 22 (4) 17 (15) 5 (1) 14.18 (5.1-39.4) 12.83 (4.2-39.2), P < 0.001
Allergic rhinitis 79 (15) 19 (17) 60 (15) 1.17 (0.7-2.0) -
Eczema 48 (9) 9 (8) 39 (9) 0.82 (0.4-1.7) -
Diabetes 40 (8) 10 (9) 30 (7) 1.22 (0.6-2.6) -
Current antibiotic§ 112 (21) 31 (27) 81 (20) 1.52 (0.9-2.4) 2.21 (1.3-3.8), P = 0.05
Hospitalization¶ 41 (8) 9 (8) 32 (8) 1.01 (0.5-2.2) -
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio; CI, confidence interval.
*Adjusted for age <65, insect bite, previous MRSA, contact with MRSA patient, and current antibiotic use.
†A history of acute itching, trauma, recent surgery, or possible insect bite refers to the infected area.
‡A person with a prior history of MRSA with whom the patient had close contact (e.g. a household member).
§Current antibiotic refers to an antibiotic the patient was already taking at study entry.
¶Admission to hospital, skilled nursing facility, or dialysis unit in the last 12 months.
Table 4 Clinical variables: overall, and MRSA vs. non-MRSA












30/511 (6) 7/112 (6) 23/399 (6) 1.09 (0.5-2.6) -
Erythema ≥10 cm 93/500 (19) 38/110 (35) 55/390 (14) 3.2 (2.0 - 5.2) 2.59 (1.5-4.4), P < 0.001
Location (N = 529) (N = 115) (N = 414)
Trunk† 180 (34) 54 (47) 126 (30) 2.01 (1.3-3.1) -
Head and neck 70 (13) 12 (10) 58 (14) 0.97 (0.5-1.9) -
Extremities 279 (53) 49 (43) 230 (56) 1 -
Diagnosis group (N = 529) (N = 115) (N = 414)
Abscess 185 (35) 66 (57) 119 (29) 3.33 (2.2-5.1) 3.19 (2.1-5.0), P < 0.001
Cellulitis 183 (35) 27 (23) 156 (38) 1‡
Other SSTIs 161 (30) 22 (19) 139 (34)
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; OR, odds ratio; CI, confidence interval; SSTIs,
skin and soft-tissue infections.
* Adjusted for erythema ≥10 cm and diagnosis group.
†The trunk was defined as the body from and including the axillae to the upper one third of the thighs.
‡For modeling purposes, cellulitis and other SSTIs were grouped.
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reported in the US [1-7]. While MRSA overall was less
common in our patients, its proportion varied by risk
factors. For example, when both abscess diagnosis and
large erythema were present, MRSA was isolated in
almost 60 percent of cases. Other risk factors for MRSA
included a history of prior MRSA in the patient or a
close contact, and age <65 years. A history of prior
MRSA in the patient had a positive predictive value for
current MRSA of 88 percent. Most abscesses were trea-
ted empirically with antibiotics, although selection of a
drug to which the isolate was susceptible did not affect
the outcomes we measured. Seventeen percent of
abscesses did not undergo I&D at the initial visit, and
13 percent required a repeat I&D. Resource utilization
for abscesses was highest for those with large erythema.
There are several possible explanations for the rela-
tively low prevalence of MRSA in our patients. First,
MRSA may have simply emerged more slowly in our
region. Indeed, the prevalence of MRSA has been shown
to vary geographically [6,25]. However, a surge of
MRSA in SSTIs in the Bay Area [1,2] preceding our
study makes this unlikely. Second, demographical
differences may have contributed to a disparity in
MRSA prevalence. Our patients resided in suburban zip
codes with relatively high SES, and most had established
primary care. In contrast, patients in earlier studies were
identified in hospital-based clinics and emergency
departments of urban medical centers that serve the
poor [1-7]. Urban areas with the lowest income levels
have been shown to have the highest incidence rates of
MRSA [32], possibly related to clustering of MRSA
cases in public housing and incarceration [15]. Third,
the distribution of SSTIs into abscesses, cellulitis, and
other SSTIs was almost equal in our study. By compari-
son, abscesses predominated in several previous studies
[1,2,6]. The lower proportion of abscesses in our study
could have decreased the prevalence of MRSA as we
found MRSA to be more common in abscesses. Finally,
SSTIs in our study were not limited to those caused by
S. aureus [4,5]. Limiting our analysis to S. aureus alone
would have resulted in a MRSA prevalence of 42
percent.
Our findings have implications for the treatment of
SSTIs in primary care. For example, clinicians should
consider diagnosis type when making antibiotic selec-
tions. We found that most culturable, non-abscess
SSTIs are caused by bacteria other than MRSA. In fact,
in the other SSTIs diagnosis group the proportion of
MRSA was only 8 percent if cases of folliculitis, a poten-
tial precursor to abscess formation, were excluded.
MRSA also appears to be uncommon in non-culturable
cellulitis which is usually caused by Streptococcal spe-
cies [33,34] and responds to beta-lactam antibiotics [34].
In contrast, we found MRSA to be common in abscesses
with large erythema. Thus, antibiotics chosen for these
infections should be MRSA-active based on local sus-
ceptibility testing. However, the imperative for antibiotic
treatment of abscesses remains unclear [35-37]. Two
randomized, controlled trials (RCTs) of TMP/SMX ver-
sus placebo for the treatment of skin abscesses after
I&D showed no benefit of drug therapy in reducing
treatment failure [38,39]. From this standpoint, the high










All SSTIs (N = 500) 52/309 (17) 20/93 (22) 38/98 (39)
Abscess (N = 178) 23/91 (25) 15/43 (35) 26/44 (59)
Cellulitis (N = 165) 11/81 (14) 3/39 (8) 11/45 (24)
Other SSTIs (N = 157) 18/137 (13) 2/11 (18) 1/9 (11)
Abbreviations: MRSA, methicillin-resistant Staphylococcus aureus; SSTIs, skin
and soft-tissue infections.
Table 6 Initial antibiotic selections for abscesses (N = 172)
Antibiotic selection Abscesses, No. (%)
Beta-lactam 68 (40)
Cephalosporin 54 (31)
Amoxicillin-clavulanic acid 9 (5)
Amoxicillin 1 (1)
Dicloxacillin 1 (1)






Combination MRSA-active 6 (3)
Beta-lactam plus MRSA-active 33 (19)
Fluoroquinolone 8 (5)
Abbreviations: TMP/SMX, Trimethoprim-sulfamethoxazole; MRSA, methicillin-
resistant Staphylococcus aureus.
* Drugs typically active against MRSA by susceptibility testing at PAMF-PA.
Table 7 Resource* utilization for abscesses by erythema










Outpatient IV 3 (5) 3 (7) 18 (46)
Hospitalization 0 (0) 1 (2) 1 (3)
Repeat I&D 5 (8) 5 (12) 8(21)
≥3 Follow-Up visits 11 (18) 15 (37) 28 (72)
Any resource 14 (22) 14 (34) 30 (77)
Abbreviations: IV, Intravenous infusion; I&D, incision and drainage.
*Resources in addition to initial I&D and/or oral antibiotic treatment.
†Abscesses with follow-up information and erythema measurement.
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level of antibiotic coverage for abscesses observed in our
study (93 percent) seems excessive. However, in both
RCTs there were fewer new lesions in the TMP/SMX
group after follow-up, leaving open the possibility of a
drug benefit. Also, most abscesses in these studies had
erythema or induration of <10 cm. Thus, the validity of
their results for larger abscesses is unclear. One observa-
tional study of 531 community-acquired SSTIs (mostly
abscesses) caused by MRSA that excluded “minor or
superficial skin infections” found that lack of an active
antibiotic was a risk factor for treatment failure [19].
While we did not find an effect of active antibiotic ther-
apy on the frequency of repeat I&D or follow-up visits
for abscesses, the generalizability of our results is limited
by the small sample size and observational design of our
study.
In addition, some I&D procedures may be delayed or
inadequate. While we are not aware of validated criteria
by which to make these judgments, it is reasonable for
clinicians to consider aspiration or ultrasound imaging if
the presence of pus is unclear, or surgical consultation if
there is doubt about the examiner’s ability to perform
an I&D.
Finally, greater resources are expended on abscesses
with large erythema. Why some abscesses are large at
presentation is unknown. Possible modifiable factors
include delay in seeking medical care, attempts at self-
treatment (e.g. squeezing or even incising the abscess),
delayed or inadequate I&D, and inappropriate antibiotic
selection or route of antibiotic delivery.
Our study also has implications for the prevention of
SSTIs caused by MRSA. The strong association of prior
MRSA in the patient or a close contact with current
MRSA suggests that persistent MRSA colonization in
the individual [40], and transmission of MRSA in house-
holds [41] contribute to incident MRSA SSTIs. The
smaller proportion of SSTIs caused by MRSA among
patients ≥65 years may reflect lower potential exposure
through skin-to-skin contact or contaminated fomites as
the elderly more typically live alone [42]. De-coloniza-
tion and limiting fomite exposure among household
contacts are two possible strategies for limiting the
spread of MRSA in the community.
Limitations
There are several limitations to our study. First, only
SSTIs that produced pus or fluid were included in the
study. Excluding non-culturable cellulitis, which is lar-
gely Streptococcal in origin [33,34], may have biased our
estimation of the prevalence of MRSA upward. Second,
the decision to culture an SSTI was left to the discretion
of the provider. We do not know how many culturable
SSTIs were not cultured. However, the observation that
68 percent of SSTIs undergoing I&D in urgent care
during the study period were included in the study sug-
gests case identification was good. Third, 25 percent of
our patients were lost to follow-up and our follow-up
extended to only one week. We may have missed some
treatment failures or late complications. Finally, the
small sample size and lack of experimental design of our
study limited our ability to detect a treatment effect of
active antibiotic therapy on outcomes for abscesses.
Future studies are needed to confirm the high propor-
tion of MRSA in large abscesses, to examine the effect
of adjunctive antibiotics in the treatment of abscesses
(especially large abscesses), to define quality measures
for I&D, and to determine why some SSTIs are large at
presentation.
Conclusions
The prevalence of MRSA is relatively low in a broad
range of SSTIs diagnosed in suburban primary care. In
contrast, MRSA is the most common isolate in
abscesses with large erythema. Empirical antibiotic treat-
ment, if selected for these infections, should be active
against MRSA. Many non-abscess SSTIs do not require
empirical coverage for MRSA and over-treatment of
small abscesses with antibiotics appears to be common.
Documentation of prior MRSA in health records may
alert clinicians to the high probability of MRSA in sub-
sequent culturable SSTIs.
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